Initial antibiotic monitoring studies successful

UCL – The application of the MicroEye® for blood and other tissue monitoring for antibiotics is providing important insights into why patients may not necessarily receive the best drug therapy.  UCL has committed to purchase a state-of-the-art analytical system to enable great sample throughput now that the initial studies have been successful

Positive progress for the immunosuppressant monitoring trial

Our Nanodem study to monitor immunosuppressant drugs that prevent rejection in transplant patients, is proceeding well. We now have 12 patients completed and will continue in the next 3 weeks with additional subjects.  In addition, Probe has been invited Munich to join a consortium involving Munich as well as other German, Austrian, Danish, Spanish and…
Read more »

Evaluations continue successfully

Review of first five patients at St Peter’s and continuation of the trial Following the start of the continuous, automatic glucose monitoring trial at St Peter’s Hospital Chertsey a review has been successfully carried out on the data received from the first five patients. The trial now continues with further patients. In addition to the…
Read more »

Successful start to immunosuppressant monitoring trial

  Wednesday 18th April saw the successful start to the Nanodem immunosuppressant monitoring trial in Munich. The first two patients completed their 48 hour monitoring and further patients are planned in the next few days. In addition to monitoring the immunosuppressant cyclosporine, it was also possible to monitor the patient’s glucose. Analysis of dialysate samples are…
Read more »

Probe systems in clinical use

Probe is pleased to announce that it has started clinical evaluations of its MicroEye and ContinuMon monitoring systems. The first evaluation has commenced at St Peter’s Hospital Chertsey UK. Subsequent clinical work will commence in other centres in the New Year.